Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography
- PMID: 21750197
- DOI: 10.1158/1078-0432.CCR-10-2933
Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography
Abstract
Purpose: Tumor resistance to docetaxel may be associated with reduced drug concentrations in tumor tissue. Positron emission tomography (PET) allows for quantification of radiolabeled docetaxel ([(11)C]docetaxel) kinetics and might be useful for predicting response to therapy. The primary objective was to evaluate the feasibility of quantitative [(11)C]docetaxel PET scans in lung cancer patients. The secondary objective was to investigate whether [(11)C]docetaxel kinetics were associated with tumor perfusion, tumor size, and dexamethasone administration.
Experimental design: Thirty-four lung cancer patients underwent dynamic PET-computed tomography (CT) scans using [(11)C]docetaxel. Blood flow was measured using oxygen-15 labeled water. The first 24 patients were premedicated with dexamethasone. For quantification of [(11)C]docetaxel kinetics, the optimal tracer kinetic model was developed and a noninvasive procedure was validated.
Results: Reproducible quantification of [(11)C]docetaxel kinetics in tumors was possible using a noninvasive approach (image derived input function). Thirty-two lesions (size ≥4 cm(3)) were identified, having a variable net influx rate of [(11)C]docetaxel (range, 0.0023-0.0229 mL·cm(-3)·min(-1)). [(11)C]docetaxel uptake was highly related to tumor perfusion (Spearman's ρ = 0.815;P < 0.001), but not to tumor size (Spearman's ρ = -0.140; P = 0.446). Patients pretreated with dexamethasone showed lower [(11)C]docetaxel uptake in tumors (P = 0.013). Finally, in a subgroup of patients who subsequently received docetaxel therapy, relative high [(11)C]docetaxel uptake was related with improved tumor response.
Conclusions: Quantification of [(11)C]docetaxel kinetics in lung cancer was feasible in a clinical setting. Variable [(11)C]docetaxel kinetics in tumors may reflect differential sensitivity to docetaxel therapy. Our findings warrant further studies investigating the predictive value of [(11)C]docetaxel uptake and the effects of comedication on [(11)C]docetaxel kinetics in tumors.
Similar articles
-
Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography.Clin Cancer Res. 2013 Aug 1;19(15):4163-73. doi: 10.1158/1078-0432.CCR-12-3779. Epub 2013 Apr 25. Clin Cancer Res. 2013. PMID: 23620410
-
Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.Acad Radiol. 2013 Jan;20(1):32-40. doi: 10.1016/j.acra.2012.07.002. Epub 2012 Sep 19. Acad Radiol. 2013. PMID: 22999369
-
[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.Clin Cancer Res. 2011 Dec 15;17(24):7664-72. doi: 10.1158/1078-0432.CCR-11-0783. Epub 2011 Oct 25. Clin Cancer Res. 2011. PMID: 22028493 Clinical Trial.
-
In vivo imaging as a pharmacodynamic marker.Clin Cancer Res. 2014 May 15;20(10):2569-77. doi: 10.1158/1078-0432.CCR-13-2666. Clin Cancer Res. 2014. PMID: 24831279 Review.
-
11C-Labeled 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}.2011 Jul 22 [updated 2011 Aug 25]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2011 Jul 22 [updated 2011 Aug 25]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 21882404 Free Books & Documents. Review.
Cited by
-
Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [(11)C]docetaxel.Front Oncol. 2013 Aug 13;3:208. doi: 10.3389/fonc.2013.00208. eCollection 2013. Front Oncol. 2013. PMID: 23986880 Free PMC article.
-
Scheduling of anticancer drugs: timing may be everything.Cell Cycle. 2012 Dec 1;11(23):4339-43. doi: 10.4161/cc.22187. Epub 2012 Oct 3. Cell Cycle. 2012. PMID: 23032365 Free PMC article.
-
Restriction of drug transport by the tumor environment.Histochem Cell Biol. 2018 Dec;150(6):631-648. doi: 10.1007/s00418-018-1744-z. Epub 2018 Oct 25. Histochem Cell Biol. 2018. PMID: 30361778 Review.
-
Copper-Mediated Late-stage Radiofluorination: Five Years of Impact on Pre-clinical and Clinical PET Imaging.Clin Transl Imaging. 2020 Jun;8(3):167-206. doi: 10.1007/s40336-020-00368-y. Epub 2020 May 26. Clin Transl Imaging. 2020. PMID: 33748018 Free PMC article.
-
Desmoplastic tumor priming using clinical-stage corticosteroid liposomes.Cell Biomater. 2025 Apr 22;1(3):None. doi: 10.1016/j.celbio.2025.100051. Cell Biomater. 2025. PMID: 40276304 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous